Top

Reproductive Biology and Endocrinology

Published in:

Open Access 01-12-2010 | Review

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Authors: João Batista A Oliveira, Ricardo Baruffi, Cláudia G Petersen, Ana L Mauri, Mario Cavagna, José G Franco Jr

Published in: Reproductive Biology and Endocrinology | Issue 1/2010

Abstract

Background

The effects of gonadotrophin-releasing hormone agonist (GnRH-a) administered in the luteal phase remains controversial. This meta-analysis aimed to evaluate the effect of the administration of a single-dose of GnRH-a in the luteal phase on ICSI clinical outcomes.

Methods

The research strategy included the online search of databases. Only randomized studies were included. The outcomes analyzed were implantation rate, clinical pregnancy rate (CPR) per transfer and ongoing pregnancy rate. The fixed effects model was used for odds ratio. In all trials, a single dose of GnRH-a was administered at day 5/6 after ICSI procedures.

Results

All cycles presented statistically significantly higher rates of implantation (P < 0.0001), CPR per transfer (P = 0.006) and ongoing pregnancy (P = 0.02) in the group that received luteal-phase GnRH-a administration than in the control group (without luteal-phase-GnRH-a administration). When meta-analysis was carried out only in trials that had used long GnRH-a ovarian stimulation protocol, CPR per transfer (P = 0.06) and ongoing pregnancy (P = 0.23) rates were not significantly different between the groups, but implantation rate was significant higher (P = 0.02) in the group that received luteal-phase-GnRH-a administration. On the other hand, the results from trials that had used GnRH antagonist multi-dose ovarian stimulation protocol showed statistically significantly higher implantation (P = 0.0002), CPR per transfer (P = 0.04) and ongoing pregnancy rate (P = 0.04) in the luteal-phase-GnRH-a administration group. The majority of the results presented heterogeneity.

Conclusions

These findings demonstrate that the luteal-phase single-dose GnRH-a administration can increase implantation rate in all cycles and CPR per transfer and ongoing pregnancy rate in cycles with GnRH antagonist ovarian stimulation protocol. Nevertheless, by considering the heterogeneity between the trials, it seems premature to recommend the use of GnRH-a in the luteal phase. Additional randomized controlled trials are necessary before evidence-based recommendations can be provided.

Available only for authorised users

Devroey P, Bourgain C, Macklon NS, Fauser BC: Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. 2004, 15: 84-90. 10.1016/j.tem.2004.01.009.CrossRefPubMed

Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P: An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update. 2007, 13: 581-590. 10.1093/humupd/dmm021.CrossRefPubMed

Pritts EA, Atwood AK: Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002, 17: 2287-2299. 10.1093/humrep/17.9.2287.CrossRefPubMed

Lemay A, Faure N, Labrie F: Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women. Fertil Steril. 1982, 37: 193-200.PubMed

Lemay A, Faure N, Labrie F, Fazekas AT: Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge. Fertil Steril. 1983, 39: 661-667.PubMed

Dubourdieu S, Charbonnel B, Massai MR, Marraoui J, Spitz I, Bouchard P: Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration. Fertil Steril. 1991, 56: 440-445.PubMed

Herman A, Ron-El R, Golan A, Nachum H, Soffer Y, Caspi E: Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod. 1992, 7: 465-468.PubMed

Nillius SJ: Luteinizing hormone releasing hormone analogues for contraception. Clin Obstet Gynaecol. 1984, 11: 551-572.PubMed

Thau RB: Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review. Contraception. 1984, 29: 143-162. 10.1016/0010-7824(84)90025-8.CrossRefPubMed

10.

Balasch J, Martinez F, Jove I, Cabre L, Coroleu B, Barri PN, Vanrell JA: Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod. 1993, 8: 1148-1151.PubMed

11.

Cahill DJ, Fountain SA, Fox R, Fleming CF, Brinsden PR, Hull MG: Outcome of inadvertent administration of a gonadotrophin-releasing hormone agonist (buserelin) in early pregnancy. Hum Reprod. 1994, 9: 1243-1246.PubMed

12.

Papanikolaou EG, Platteau P, Albano C, Kolibianakis E, Devroey P: Achievement of pregnancy three times in the same patient during luteal GnRH agonist administration. Reprod Biomed Online. 2005, 10: 347-349. 10.1016/S1472-6483(10)61794-4.CrossRefPubMed

13.

Platteau P, Gabbe M, Talbot M, Healy D: Two consecutive pregnancies during inadvertent gonadotropin-releasing hormone agonist desensitization. Fertil Steril. 2000, 73: 1244-1246. 10.1016/S0015-0282(00)00536-7.CrossRefPubMed

14.

Tan HH, Yeong CT, Loh KE: Perinatal outcome of pregnancies after inadvertent exposure to gonadotrophin-releasing hormone analogue. Aust N Z J Obstet Gynaecol. 2006, 46: 336-340. 10.1111/j.1479-828X.2006.00602.x.CrossRefPubMed

15.

Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, Vicdan K: Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online. 2009, 19: 472-477. 10.1016/j.rbmo.2009.04.001.CrossRefPubMed

16.

Razieh DF, Maryam AR, Nasim T: Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection. Taiwan J Obstet Gynecol. 2009, 48: 245-248. 10.1016/S1028-4559(09)60297-7.CrossRefPubMed

17.

Tesarik J, Hazout A, Mendoza C: Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004, 19: 1176-1180. 10.1093/humrep/deh235.CrossRefPubMed

18.

Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C: Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006, 21: 2572-2579. 10.1093/humrep/del173.CrossRefPubMed

19.

Fujii S, Sato S, Fukui A, Kimura H, Kasai G, Saito Y: Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod. 2001, 16: 1671-1675. 10.1093/humrep/16.8.1671.CrossRefPubMed

20.

Qublan H, Amarin Z, Al-Qudah M, Diab F, Nawasreh M, Malkawi S, Balawneh M: Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of <or = 7 mm on day of egg retrieval. Hum Fertil (Camb). 2008, 11: 43-47. 10.1080/14647270701704768.CrossRef

21.

Pirard C, Donnez J, Loumaye E: GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod. 2005, 20: 1798-1804. 10.1093/humrep/deh830.CrossRefPubMed

22.

Pirard C, Donnez J, Loumaye E: GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006, 21: 1894-1900. 10.1093/humrep/del072.CrossRefPubMed

23.

Ata B, Urman B: Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?. Reprod Biomed Online. 2010, 20: 165-166. 10.1016/j.rbmo.2009.10.022.CrossRefPubMed

24.

Ata B, Yakin K, Balaban B, Urman B: GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum Reprod. 2008, 23: 668-673. 10.1093/humrep/dem421.CrossRefPubMed

25.

Isikoglu M, Ozgur K, Oehninger S: Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. J Reprod Med. 2007, 52: 639-644.PubMed

26.

Casan EM, Raga F, Polan ML: GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod. 1999, 5: 234-239. 10.1093/molehr/5.3.234.CrossRefPubMed

27.

Kawamura K, Fukuda J, Kumagai J, Shimizu Y, Kodama H, Nakamura A, Tanaka T: Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. Endocrinology. 2005, 146: 4105-4116. 10.1210/en.2004-1646.CrossRefPubMed

28.

Nam DH, Lee SH, Kim HS, Lee GS, Jeong YW, Kim S, Kim JH, Kang SK, Lee BC, Hwang WS: The role of gonadotropin-releasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization. Theriogenology. 2005, 63: 190-201. 10.1016/j.theriogenology.2004.04.004.CrossRefPubMed

29.

Raga F, Casan EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML: The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology. 1999, 140: 3705-3712. 10.1210/en.140.8.3705.PubMed

30.

Islami D, Chardonnens D, Campana A, Bischof P: Comparison of the effects of GnRH-I and GnRH-II on HCG synthesis and secretion by first trimester trophoblast. Mol Hum Reprod. 2001, 7: 3-9. 10.1093/molehr/7.1.3.CrossRefPubMed

31.

Lin LS, Roberts VJ, Yen SS: Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab. 1995, 80: 580-585. 10.1210/jc.80.2.580.PubMed

32.

Klemmt PA, Liu F, Carver JG, Jones C, Brosi D, Adamson J, Mardon HJ, McVeigh E: Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum Reprod. 2009, 24: 2187-2192. 10.1093/humrep/dep181.PubMedCentralCrossRefPubMed

33.

Raga F, Casan EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML: Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod. 1998, 59: 661-669. 10.1095/biolreprod59.3.661.CrossRefPubMed

34.

Shemesh M: Actions of gonadotrophins on the uterus. Reproduction. 2001, 121: 835-842. 10.1530/rep.0.1210835.CrossRefPubMed

35.

Chou CS, Tai CJ, MacCalman CD, Leung PC: Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual Stromal cells in vitro. J Clin Endocrinol Metab. 2003, 88: 680-688. 10.1210/jc.2002-021277.CrossRefPubMed

36.

Raga F, Casan EM, Wen Y, Huang HY, Bonilla-Musoles F, Polan ML: Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab. 1999, 84: 636-642. 10.1210/jc.84.2.636.PubMed

37.

Meresman GF, Bilotas MA, Lombardi E, Tesone M, Sueldo C, Baranao RI: Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod. 2003, 18: 1767-1771. 10.1093/humrep/deg356.CrossRefPubMed

38.

Wu HM, Wang HS, Huang HY, Soong YK, MacCalman CD, Leung PC: GnRH signaling in intrauterine tissues. Reproduction. 2009, 137: 769-777. 10.1530/REP-08-0397.CrossRefPubMed

39.

Zhang X, Bocca S, Franchi A, Anderson S, Kaur M, Bajic VB, Oehninger S: Do GnRH analogues directly affect human endometrial epithelial cell gene expression?. Mol Hum Reprod. 2010, 16: 347-360. 10.1093/molehr/gaq012.CrossRefPubMed

40.

Hugues JN, Cedrin-Durnerin I, Bstandig B, Theron-Gerard L, Grange D, Laffy A, Clement P, Hamidi J, Sifer C, Poncelet C: Administration of gonadotropin-releasing hormone agonist during the luteal phase of GnRH-antagonist IVF cycles. Hum Reprod. 2006, 21: i3-

Title: Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis
Authors: João Batista A Oliveira
Ricardo Baruffi
Cláudia G Petersen
Ana L Mauri
Mario Cavagna
José G Franco Jr
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Reproductive Biology and Endocrinology / Issue 1/2010
Electronic ISSN: 1477-7827
DOI: https://doi.org/10.1186/1477-7827-8-107

At a glance: The STEP trials

Springer Medicine

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Profiling spermatogenic failure in adult testes bearing Sox9-deficient Sertoli cells identifies genes involved in feminization, inflammation and stress

Neurokinin B and pre-eclampsia: a decade of discovery

Impact of methoxyacetic acid on mouse Leydig cell gene expression

Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells

The impact of maternal protein restriction during rat pregnancy upon renal expression of angiotensin receptors and vasopressin-related aquaporins